Pharma 3.0: A Call for Collaboration and Experimentation


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

Success or failure in Pharma 3.0 — an ecosystem comprised of established industry members, nontraditional companies, and an increasingly informed data-empowered consumer — will be based on life-sciences companies’ ability to develop innovative, outcomes-focused offerings through structured, systematic, and scalable approaches to business model innovation. The two most prevalent elements that will separate the winners and losers in Pharma 3.0 in the coming year are radical business model experimentation and collaboration. Not only will companies have to jockey for a spot among the usual industry competitors, but nonindustry investors that are getting in the game also pose a threat…

Four Keys to Success in the Pharma 3.0 Era
Nontraditional Partnerships Require Nontraditional Views

R.T. (Terry) Hisey. Vice ­Chairman, U.S. Industry Leader, Life Sciences Practice, ­Deloitte LLP, a provider of audit, tax, consulting, and ­financial advisory ­services. For more ­information, visit
Carolyn Buck Luce. Global Pharmaceutical Sector Leader, Ernst & Young, which helps ­companies to identify and capitalize on business ­opportunities. For more information, visit
Usama Malik. VP, Worldwide Innovation, Pfizer Inc., a ­research-based pharmaceutical company. For more information, visit
Kimberly Park. Partner, Janssen Healthcare ­Innovation, Johnson & Johnson, a global pharmaceutical, medical devices, and ­consumer packaged goods manufacturer. For more information, visit
Nagaraja Srivatsan. Senior VP and Head of Life Sciences, North America, ­Cognizant, which offers information technology, consulting, and business process outsourcing services. For more information, visit
Ann Walz. CEO, Medisys, which is ­focused on scientific platform ­development and message evolution. For more information, visit